A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2009
This study is designed to determine whether patients previously primed with Ad5 of MRKAd5 HIV-1 gag vaccine respond better when boosted with ALVAC-HIV vaccine than when boosted with MKRAd5 HIV-1 gag vaccine.
Epistemonikos ID: 85f3328b57fd3fac55ea54d1214988ae27cf0e9c
First added on: Dec 01, 2021